Several PI3K/AKT/mTOR-targeted therapies, such as buparlisib (PI3K inhibitor), MK2206 (AKT inhibitor), sirolimus (mTOR inhibitor), and perifosine (dual PI3K/AKT inhibitor), are undergoing clinical trials as treatments for lung cancer [21,22,23,24]. Here, MTOR is linked to lung carcinoma.